Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival

IMPACT Trialists, Mitch Dowsett, Ian E Smith, Steve R Ebbs, J Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh

Research output: Contribution to journalArticlepeer-review

Abstract

Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up. The aim of this study--as part of the Immediate Preoperative "Arimidex" (anastrozole), Tamoxifen, or Arimidex Combined with Tamoxifen (IMPACT) trial (n = 330)--was to test the hypotheses that changes in Ki-67 after 2 weeks and/or 12 weeks: (i) differed between treatments, (ii) predicted clinical tumor response, and/or (iii) may predict long-term outcome differences between treatments in adjuvant therapy.
Original languageEnglish
Pages (from-to)951s-8s
JournalClinical Cancer Research
Volume11
Issue number2 Pt 2
Publication statusPublished - 15 Jan 2005

Keywords

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Breast Neoplasms
  • Cell Proliferation
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Ki-67 Antigen
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local
  • Nitriles
  • Survival Rate
  • Tamoxifen
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival'. Together they form a unique fingerprint.

Cite this